Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma

Yutaka Suto, Mariko Sato, Kota Fujimori, Shotaro Kitabatake, Mikio Okayama, Daijyu Ichikawa, Maiko Matsushita, Noriyuki Yamagiwa, Genji Iwasaki, Fumiyuki Kiuchi, Yutaka Hattori

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Alternatives of treatments for multiple myeloma (MM) have become increasingly available with the advent of new drugs such as proteasome inhibitors, thalidomide derivatives, histone deacetylase inhibitors, and antibody drugs. However, high-risk MM cases that are refractory to novel drugs remain, and further optimization of chemotherapeutics is urgently needed. We had achieved asymmetric total synthesis of komaroviquinone, which is a natural product from the plant Dracocephalum komarovi. Similar to several leading antitumor agents that have been developed from natural compounds, we describe the antitumor activity and cytotoxicity of komaroviquinone and related compounds in bone marrow cells. Our data suggested that komaroviquinone-related agents have potential as starting compounds for anticancer drug development.

Original languageEnglish
Pages (from-to)4558-4563
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume27
Issue number19
DOIs
Publication statusPublished - 2017 Oct 1

Fingerprint

Lead compounds
Biological Products
Multiple Myeloma
Pharmaceutical Preparations
Proteasome Inhibitors
Histone Deacetylase Inhibitors
Thalidomide
Therapeutics
Cytotoxicity
Bone Marrow Cells
Antineoplastic Agents
Refractory materials
Bone
Cells
Derivatives
komaroviquinone
Lead
Antibodies

Keywords

  • Antitumor reagent
  • Multiple myeloma
  • Natural product

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma. / Suto, Yutaka; Sato, Mariko; Fujimori, Kota; Kitabatake, Shotaro; Okayama, Mikio; Ichikawa, Daijyu; Matsushita, Maiko; Yamagiwa, Noriyuki; Iwasaki, Genji; Kiuchi, Fumiyuki; Hattori, Yutaka.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 27, No. 19, 01.10.2017, p. 4558-4563.

Research output: Contribution to journalArticle

@article{b0da1e4c15aa4c558bc26e63691f10a1,
title = "Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma",
abstract = "Alternatives of treatments for multiple myeloma (MM) have become increasingly available with the advent of new drugs such as proteasome inhibitors, thalidomide derivatives, histone deacetylase inhibitors, and antibody drugs. However, high-risk MM cases that are refractory to novel drugs remain, and further optimization of chemotherapeutics is urgently needed. We had achieved asymmetric total synthesis of komaroviquinone, which is a natural product from the plant Dracocephalum komarovi. Similar to several leading antitumor agents that have been developed from natural compounds, we describe the antitumor activity and cytotoxicity of komaroviquinone and related compounds in bone marrow cells. Our data suggested that komaroviquinone-related agents have potential as starting compounds for anticancer drug development.",
keywords = "Antitumor reagent, Multiple myeloma, Natural product",
author = "Yutaka Suto and Mariko Sato and Kota Fujimori and Shotaro Kitabatake and Mikio Okayama and Daijyu Ichikawa and Maiko Matsushita and Noriyuki Yamagiwa and Genji Iwasaki and Fumiyuki Kiuchi and Yutaka Hattori",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.bmcl.2017.08.054",
language = "English",
volume = "27",
pages = "4558--4563",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "19",

}

TY - JOUR

T1 - Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma

AU - Suto, Yutaka

AU - Sato, Mariko

AU - Fujimori, Kota

AU - Kitabatake, Shotaro

AU - Okayama, Mikio

AU - Ichikawa, Daijyu

AU - Matsushita, Maiko

AU - Yamagiwa, Noriyuki

AU - Iwasaki, Genji

AU - Kiuchi, Fumiyuki

AU - Hattori, Yutaka

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Alternatives of treatments for multiple myeloma (MM) have become increasingly available with the advent of new drugs such as proteasome inhibitors, thalidomide derivatives, histone deacetylase inhibitors, and antibody drugs. However, high-risk MM cases that are refractory to novel drugs remain, and further optimization of chemotherapeutics is urgently needed. We had achieved asymmetric total synthesis of komaroviquinone, which is a natural product from the plant Dracocephalum komarovi. Similar to several leading antitumor agents that have been developed from natural compounds, we describe the antitumor activity and cytotoxicity of komaroviquinone and related compounds in bone marrow cells. Our data suggested that komaroviquinone-related agents have potential as starting compounds for anticancer drug development.

AB - Alternatives of treatments for multiple myeloma (MM) have become increasingly available with the advent of new drugs such as proteasome inhibitors, thalidomide derivatives, histone deacetylase inhibitors, and antibody drugs. However, high-risk MM cases that are refractory to novel drugs remain, and further optimization of chemotherapeutics is urgently needed. We had achieved asymmetric total synthesis of komaroviquinone, which is a natural product from the plant Dracocephalum komarovi. Similar to several leading antitumor agents that have been developed from natural compounds, we describe the antitumor activity and cytotoxicity of komaroviquinone and related compounds in bone marrow cells. Our data suggested that komaroviquinone-related agents have potential as starting compounds for anticancer drug development.

KW - Antitumor reagent

KW - Multiple myeloma

KW - Natural product

UR - http://www.scopus.com/inward/record.url?scp=85028697647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028697647&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2017.08.054

DO - 10.1016/j.bmcl.2017.08.054

M3 - Article

C2 - 28882484

AN - SCOPUS:85028697647

VL - 27

SP - 4558

EP - 4563

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 19

ER -